Pulmonx Co. (NASDAQ:LUNG) Receives Average Recommendation of "Moderate Buy" from Analysts

Pulmonx Co. (NASDAQ:LUNG - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eight analysts that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $12.75.

LUNG has been the topic of a number of analyst reports. Morgan Stanley began coverage on Pulmonx in a research note on Monday, March 10th. They issued an "equal weight" rating for the company. Jefferies Financial Group initiated coverage on shares of Pulmonx in a report on Monday, March 10th. They set a "buy" rating for the company. D. Boral Capital assumed coverage on shares of Pulmonx in a research report on Monday, March 10th. They set a "buy" rating and a $17.00 price objective for the company. Finally, Citigroup started coverage on Pulmonx in a report on Monday, March 10th. They issued a "buy" rating on the stock.

Insider Activity at Pulmonx

In related news, Director Glendon E. French III sold 55,453 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $8.28, for a total value of $459,150.84. Following the sale, the director now owns 1,011,974 shares in the company, valued at $8,379,144.72. This represents a 5.20 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Geoffrey Beran Rose sold 5,779 shares of Pulmonx stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $7.13, for a total value of $41,204.27. Following the transaction, the insider now directly owns 285,278 shares of the company's stock, valued at approximately $2,034,032.14. This represents a 1.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 145,660 shares of company stock worth $1,128,484 over the last 90 days. Company insiders own 5.70% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. State Street Corp raised its position in Pulmonx by 2.6% during the third quarter. State Street Corp now owns 747,028 shares of the company's stock worth $6,193,000 after acquiring an additional 18,592 shares during the last quarter. Barclays PLC lifted its stake in shares of Pulmonx by 1.8% during the third quarter. Barclays PLC now owns 94,109 shares of the company's stock valued at $780,000 after buying an additional 1,679 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Pulmonx by 1.3% during the third quarter. Geode Capital Management LLC now owns 892,786 shares of the company's stock worth $7,403,000 after purchasing an additional 11,151 shares during the last quarter. Franklin Resources Inc. grew its holdings in Pulmonx by 2.3% in the 3rd quarter. Franklin Resources Inc. now owns 700,389 shares of the company's stock valued at $5,806,000 after buying an additional 15,570 shares during the period. Finally, 272 Capital LP acquired a new stake in shares of Pulmonx in the third quarter worth approximately $48,000. Institutional investors and hedge funds own 91.04% of the company's stock.

Pulmonx Stock Up 4.8 %

Shares of NASDAQ LUNG traded up $0.23 during midday trading on Tuesday, hitting $4.99. The company's stock had a trading volume of 315,802 shares, compared to its average volume of 318,182. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.70 and a quick ratio of 6.77. The firm has a market capitalization of $200.83 million, a price-to-earnings ratio of -3.47 and a beta of 0.61. The business's fifty day simple moving average is $6.88 and its two-hundred day simple moving average is $6.63. Pulmonx has a 1 year low of $4.15 and a 1 year high of $10.01.

Pulmonx (NASDAQ:LUNG - Get Free Report) last issued its quarterly earnings results on Wednesday, February 19th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.12. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. The company had revenue of $23.77 million during the quarter, compared to analysts' expectations of $22.29 million. On average, equities analysts predict that Pulmonx will post -1.55 EPS for the current year.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.